Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD)

被引:10
|
作者
Russo, Patrizia [1 ]
Prinzi, Giulia [1 ]
Lamonaca, Palma [1 ]
Cardaci, Vittorio [2 ]
Fini, Massimo [3 ]
机构
[1] IRCCS San Raffaele Pisana, Unit Clin & Mol Epidemiol, Via Valcannuta 247, I-00166 Rome, Italy
[2] IRCCS San Raffaele Pisana, Unit Pulm Rehabil, Via Pisana 235, I-00163 Rome, Italy
[3] IRCCS San Raffaele Pisana, Sci Direct, Via Valcannuta 247, I-00166 Rome, Italy
关键词
Cardiovascular Disease Reduction; COPD; flavonoids; pathophysiological mechanisms; rehabilomics; inflammatory disease; comorbidity; CORONARY-HEART-DISEASE; ENDOTHELIAL FUNCTION; LIPID PROFILE; METAANALYSIS; COCOA; MANAGEMENT; RISK; MECHANISMS; CONSUMPTION; PREVALENCE;
D O I
10.2174/0929867325666180514100640
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases (CV) Often Coexist. COPD and CVD are complex diseases characterized by a strict interaction between environment and genetic. The mechanisms linking these two diseases are complex, multifactorial and not entirely understood, influencing the therapeutic approach. COPD is characterized by several comorbidities, it hypothesized the treatment of cardiovascular co-morbidities that may reduce morbidity and mortality. Flavonoids are an important class of plant low molecular weight Secondary Metabolites (SMs). Convincing data from laboratory, epidemiological, and human clinical studies point the important effects on CVD risk prevention. Objective: This review aims to provide up-to-date information on the ability of Flavonoids to reduce the CVD risk. Conclusion: Current studies support the potential of Flavonoids to prevent the risk of CVD. Well-designed clinical studies are suggested to evaluate advantages and limits of Flavonoids for managing CVD comorbidity in COPD.
引用
收藏
页码:7048 / 7058
页数:11
相关论文
共 50 条
  • [1] Undertreating cardiovascular disease in people with chronic obstructive pulmonary disease (COPD)
    Gershon, Andrea S.
    Blazer, Alina
    Ko, Dennis
    [J]. THORAX, 2024, 79 (08) : 705 - 706
  • [2] Systemic inflammation and cardiovascular disease in chronic obstructive pulmonary disease (COPD)
    Gudmundsson, Gunnar
    Margretardottir, Olof
    Aspelund, Thor
    Gudnason, Vilmundur
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [3] Economic Burden of comorbid Cardiovascular disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD) patients in a managed care population
    Dalal, A. A.
    Shah, M.
    Lunacsek, O.
    Hanania, N. A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [4] Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients
    Curkendall, SM
    DeLuise, C
    Jones, JK
    Lanes, S
    Stang, MR
    Goehring, E
    She, DW
    [J]. ANNALS OF EPIDEMIOLOGY, 2006, 16 (01) : 63 - 70
  • [5] Chronic obstructive pulmonary disease (COPD)
    Feetham, Laura
    van Dorn, Aaron
    [J]. LANCET RESPIRATORY MEDICINE, 2017, 5 (01): : 18 - 19
  • [6] Chronic Obstructive Pulmonary Disease (COPD)
    Kostikas, Konstantinos
    Hillas, Georgios
    Michaelides, Stylianos A.
    Kontakiotis, Theodore
    Kosmas, Epameinondas N.
    Tzanakis, Nikolaos
    [J]. PNEUMON, 2012, 25 : 17 - 23
  • [7] Chronic Obstructive Pulmonary Disease (COPD)
    Lareau, Suzanne C.
    Fahy, Bonnie
    Meek, Paula
    Wang, Angela
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199 (01)
  • [8] Chronic Obstructive Pulmonary Disease (COPD)
    Gillissen, Adrian
    Rasche, Kurt
    [J]. MEDIZINISCHE KLINIK, 2006, 101 (07): : 559 - 570
  • [9] Chronic obstructive pulmonary disease (COPD)
    Pahl, Andreas
    Szelenyi, Istvan
    [J]. DRUGS OF THE FUTURE, 2007, 32 (09) : 799 - 807
  • [10] Chronic Obstructive Pulmonary Disease (COPD)
    Weitzenblum, E.
    [J]. EUROPEAN RESPIRATORY REVIEW, 2009, 18 (112): : 133 - 133